SNX-111 neuron-specific calcium channel blocker: The indication for the Phase I/II trial will be expanded to include a wider population with cancer pain, and to

By WIR Staff | May 22, 1995 | 7:00 AM GMT

Neurex Corp. (NXCO), Menlo Park, Calif.
Product: SNX-111 neuron-specific

Read the full 91 word article

How to gain access

Continue reading with a
two-week free trial.